Search clinical trials for: DA-5223-R

Total 2392 results

1
2
3
4
5
6
7
8
9
10
...
47
48
›

Dong-A ST Co., Ltd.

Completed

A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult Subjects

Healthy Adult

Korea, Republic of
Dong-A ST Co., Ltd.

Recruiting

A Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects

Healthy Adult

South Korea
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Withdrawn

A Study to Evaluate the Food Effect on the Pharmacokinetics of DA-5223 in Healthy Adult Subjects

Healthy Adult

South Korea
Dong-A ST Co., Ltd.

Not yet recruiting

Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects in Fed State

Healthy

South Korea
Dong-A ST Co., Ltd.

Completed

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

Hepatitis B

Korea, Republic of
Dong-A ST Co., Ltd.

Not yet recruiting

To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Not yet recruiting

A Study to Evaluate the Bioequivalence of DA-5230 Compared to DA-5230-R

Healthy Adult Participants
Dong-A ST Co., Ltd.

Completed

Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fed State

Healthy

South Korea
Dong-A ST Co., Ltd.

Completed

Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State

Healthy

South Korea
Dong-A ST Co., Ltd.

Completed

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811)

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects

Infective Disorder

South Korea
Dong-A ST Co., Ltd.

Recruiting

A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Clinical Trial of DA-5212 in Patients with Functional Dyspepsia

Functional Dyspepsia

Korea, Republic of
Dong-A ST Co., Ltd.

Not yet recruiting

Bioequivalence Study Between "DA-5215 Tab" and "DA-5215-R Tab"

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fed State

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fasting State

Healthy

Korea, Republic of
Dana-Farber Cancer Institute
Genentech, Inc.

Active, not recruiting

A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

Richter Syndrome

United States
Nordic Lymphoma Group
Helsinki University Central Hospital; Aarhus University Hospital

Active, not recruiting

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis (Bio-CHIC)

Lymphoma, Large B-Cell, Diffuse

Norway, Denmark, Sweden, Finland
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bayer; Dendreon

Completed

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the Bone

United States
Bayer

Completed

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223 (BELFIGO)

Prostatic Neoplasms, Castration-Resistant

Belgium
Bayer

No longer available

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Prostatic Neoplasms

United States
Bayer

Completed

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Prostate Cancer | Pharmacokinetics | Metastases

United States
Shandong Provincial Hospital

Recruiting

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | B-cell NonHodgkin Lymphoma

China
Bayer

Completed

BAY88-8223, Does Response Study in HRPC Patients

Bone Metastases | Hormone Refractory Prostate Cancer
Bayer

Completed

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

Prostate Cancer

United States
Bayer

Completed

Treatment Patterns in Metastatic Prostate Cancer

Prostatic Neoplasm

United States
Bayer

Completed

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

Neoplasm Metastasis

Sweden, Norway
Bayer

Completed

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Neoplasm Metastasis | Prostate Cancer

Sweden, United Kingdom
Bayer

Completed

Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body (REACTIVATE)

Prostate Cancer

Canada
Bayer

Completed

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) (EPIX)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Bayer

Completed

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

Prostatic Neoplasms

China, Singapore, Taiwan, Korea, Republic of
Bayer

Completed

A Drug Utilization Study of Radium-223 in Sweden

Neoplasms

Sweden
Bayer

Completed

Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone (RAPIT)

Castration-resistant Prostate Cancer

Taiwan
Bayer

Completed

Treatment Satisfaction With Ra-223 in Japan

Prostatic Neoplasms

Japan
Bayer

Terminated

A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels (CREDIT)

Bone Metastases | Metastatic Castration-resistant Prostate Cancer

China
Bayer

Completed

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases (PARABO)

Castration-Resistant Prostatic Cancer

Germany
Bayer

Completed

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Prostatic Neoplasms

United States, Israel, Spain, Italy, Sweden, Norway, Finland
Bayer

Completed

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Prostatic Neoplasms

Belgium, Spain, Canada, France, Switzerland, Germany, United Kingdom, Denmark, Russian Federation, Sweden, Israel, Italy, Netherlands, Norway, Czech Republic, Finland, Poland, Ireland, Mexico
Bayer

Completed

Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

Prostatic Neoplasms

Japan
Bayer

Completed

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
Bayer

Completed

A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before (DIRECT)

Bone Metastatic Castration-resistant Prostate Cancer

Germany, Netherlands, Denmark
Bayer

Completed

Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer ) (Navigant)

Prostatic Neoplasms, Castration-Resistant

United States
Bayer

Completed

BAY88-8223, Dose Finding Study in Patients With HRPC

Neoplasm Metastasis | Prostate Cancer

United Kingdom
Bayer

Completed

A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety (QOLRAD)

Prostate Cancer

Colombia
Bayer

Completed

Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany (URANIS)

Prostatic Neoplasms, Castration-Resistant

Germany

1
2
3
4
5
6
7
8
9
10
...
47
48
›

Subscribe